| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | SB590885 | GDSC1000 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | betulinic acid | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.002 | 0.9 |